The ability to accurately detect M. tuberculosis directly from clinical specimens using nucleic acid amplification (NAA) tests provides significant advantages for the management and infection control of the disease (6) . In the United States, only two FDA approved NAA tests, the Roche Amplicor Mtb PCR (PCR) and Gen-Probe MTD (MTD) assays have been available. The Roche Amplicor Mtb PCR assay was discontinued in early 2010 leaving many laboratories with only one commercially available option.
While both assays have provided benefits, neither has offered a practical solution for all levels of clinical and public health laboratories, hence specimens are often referred to reference laboratories.
Cepheid has recently introduced the GeneXpert MTB/RIF assay (RUO) (Cepheid, Sunnyvale, CA) (4) . The GeneXpert assay is a real-time PCR test that will simultaneously identify M. tuberculosis and detect rifampin resistance directly from clinical specimens (10) . Rifampin resistance can serve as a marker for MDR-TB and has been reported in > 95% of the multi-drug resistant M. tuberculosis (MDR-TB) isolates (2, 8, 12) . The GeneXpert assay detects an 81 base pair "core" region of the rpoB gene.
The test utilizes five molecular beacons that detect mutations in the core region that are associated with rifampin resistance.
To date, studies assessing the GeneXpert assay have focused entirely on specimens from patients tested outside of the United States (3, 4) . The objectives of this multi-site study were to evaluate the performance of the GeneXpert assay for the direct detection of M. tuberculosis in respiratory specimens of patients from within the United States and to evaluate the ability of the assay to detect rifampin resistance in a low prevalence population.
Two hundred and seventeen specimens (126 acid-fast smear-positive and 91 smear-negative), ordered for routine mycobacterial testing were included in the study.
Specimens were collected and tested at three different sites in the Western United States.
Specimens that could not be tested immediately after processing were stored at -80ºC.
The N-acetyl-L-cysteine-NaOH (NALC-NaOH) method was used to digest, decontaminate, and concentrate respiratory specimens (11 (11) . A smear of the processed sediment was prepared, stained, read, and results reported according to published standards (11) . Mycobacterium isolates were identified using high performance liquid chromatography, gas liquid chromatography, DNA probes (Gen-Probe Incorporated, San Diego, CA), and/or biochemical tests. All molecular testing was performed on processed sediment. Anti-mycobacterial susceptibility testing was performed by a broth microdilution method. result there was a 96% agreement for specimens with smear results of 1+/2+ (i.e., "rare"/ "few") and 100% agreement with those that were smear 3+ /4+ ("moderate"/ "numerous"). One bronchial specimen, which was smear, culture, and MTD negative, demonstrated inhibition with the GeneXpert and PCR and is not included in Table 1 .
Previously, the sensitivity of the GeneXpert system in detecting smear-positive specimens has been reported to be 98-100% and detection of rifampin resistance to be 98% in population outside the United States with high rifampin resistance (4, 10) . Overall in this study the sensitivity was 89% for the direct identification of M. tuberculosis from sputum and bronchial specimens, which rose to 98% in smear-positive specimens.
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Fourteen specimens that were culture positive tested negative by the GeneXpert (Table   1 ). Twelve of these 14 specimens were smear-negative and two had a smear result of rare or few. This is an understandable result as it has been shown that smear results, which are indicative of organism burden, are less sensitive than culture and requires 5 x 10 3 to 1 x 10 4 bacilli/mL of specimen to generate a positive result (1) . With regard to specificity, four specimens that were GeneXpert-positive and culture-negative (Table 1) were true positives. Three of four were from patients treated for tuberculosis and likely represented the detection of non-viable organisms. The other specimen was from a patient that had subsequent positive cultures. Three of four of these specimens were positive by at least one other NAA test.
The analytical limit of detection of the GeneXpert assay is reported to be 131 CFU/ml of specimen based on spiked sputum studies (3). Culture of concentrated specimens can detect very low concentrations of organisms, as low as 10-100 CFU/mL (1) . When testing at the lower limits of any assay, variability is to be expected due to factors such as sampling. As has been suggested previously, because we used frozen archived specimens, the freeze-thaw cycle may have altered sputum viscosity, improving mycobacterial nucleic acid recovery (10) . Overall, the GeneXpert assay is simple, fast, accurate and cost comparative to other commercial available PCR assays for the direct detection of M. tuberculosis.
Cepheid supplied the GeneXpert MTB/RIF assays and Gen-Probe for supplied the MTD kits for this study. 
